International Biotechnology Trust Plc -177.9% potential downside indicated by Barclays

International Biotechnology Trust Plc with ticker (LON:IBT) now has a potential downside of -177.9% according to Barclays.



Barclays set a target price of 260 GBX for the company, which when compared to the International Biotechnology Trust Plc share price of 723 GBX at opening today (25/11/2021) indicates a potential downside of -177.9%. Trading has ranged between 669 (52 week low) and 862 (52 week high) with an average of 57,988 shares exchanging hands daily. The market capitalisation at the time of writing is £302,030,905.

International Biotechnology Trust plc is an investment trust company. The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company will seek to achieve its objective by investing in a diversified portfolio of companies, which may be quoted or unquoted and whose shares are considered to have growth prospects, with experienced management and strong potential upside through the development and/or commercialization of a product, device or enabling technology. It may invest through equities, index-linked securities and debt securities, cash deposits, money market instruments and foreign currency exchange transactions. Investments may also be made in related sectors, such as medical devices and healthcare services. Its portfolio is split between large, mid and small-capitalization companies, primarily quoted on stock exchanges in North America. Its investment manager is SV Life Sciences Managers LLP.